Mark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
CSL Ltd CSL
News
-
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
CSL Says 1st Half Profit Rises, Boosts Dividend — Update
CSL Says 1st Half Profit Rises, Boosts Dividend
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
CSL Says Cardiovascular Drug CSL112 Didn't Meet 'Efficacy Endpoint' After Study
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
CSL's Hemgenix Authorized by Health Canada as Gene Therapy for Hemophilia B
CSL Annual Profit Rises 8% at Constant FX
CSL Forecasts 13-18% Growth in Fiscal Year 2024 Net Profit
Travere Therapeutics Shares Touch 52-Week Low on FSGS Study Data